{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 64,
  "pageCount": 90,
  "prevPage": 63,
  "nextPage": 65,
  "slideType": "thesis_headline",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/64",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-64",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92e9a721-1cb4-42a4-bced-110d9ea10c6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.65,
        "y": 0.39
      },
      "kind": "list",
      "text": "Target Population: Potential as monotherapy or in combination in range of haematology and oncology indications, including those with brain metastases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43df3566-bb09-4e36-93cc-530b20711788",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.07,
        "y": 0.39
      },
      "kind": "list",
      "text": "Better Design: Improved therapeutic index from low projected human dose, predicted human PK and reversible mechanism. Highly selective. Brain penetrant.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ae6ecbe-dcac-44bd-8257-8f792ad5e642",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.36,
        "y": 0.39
      },
      "kind": "list",
      "text": "Mechanistic Rationale: Promotes differentiation pathways leading to tumour cell death and/or higher sensitivity to standard of care in oncology indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9e17e02-4b86-478f-a330-5b41e0dc8b07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.38,
        "x": 0.31,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "IND-enabling studies complete\nPhase 1 expected to start in 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1fd8254-9b35-432f-91b3-6c11f78d1048",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "First precision designed molecule to tackle reversibility and brain penetrance",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59d34722-b075-491c-9159-4f46600d9087",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘539: Highly differentiated LSD1 inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1af1806-c9ed-46b9-a3cc-74e223a4a58c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 90,
      "from": 21,
      "beatId": "08c298bd-8dc4-4aa8-832d-c7b35097d152",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The presentation deck ends with a call to action, encouraging investors to take action",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}